Tiba’s co-founder and mRNA visionary, Christian Mandl, spoke at the Global Vaccine and Immunization Research Forum 2021, the central forum for research related to the mmunization Agenda 2030 (IA2030). GVIRF is the only global meeting that brings together the entire Vaccine and Immunization Research community, from basic immunology to implementation research, and from low to high income countries.
Nucleic acid vaccines: Is it all done?
Appearing in Workshop 2 Emerging Platforms, Dr. Mandl delivered a presentation looking back, and to the future, of mRNA vaccines.
From the Workshop 2: Immunoprophylaxis is an effective strategy for disease prevention and has greatly improved public health worldwide. Conventional vaccine approaches, such as inactivating or attenuating the respective pathogen, have successfully decreased the burden of many infectious diseases but have not worked for many others. Alternative approaches are being employed to address unmet medical needs. Rapid response technology platforms are also needed as new threats develop. In recent decades, the number of strategies has been significantly expanded. In this workshop, we will discuss existing and new vaccine and immunoprophylaxis platforms that have the potential to tackle current global health challenges such as COVID-19 and influenza. This session will include key updates on Emerging Vaccines Platforms, Adjuvants, and Universal Influenza Vaccines. Each speaker will present on overview of technology platforms in the field and describe applications for specific infectious disease targets and indications. The speakers will discuss preclinical data, clinical trial data, manufacturing, formulation, delivery, and regulatory pathways. In addition, the speakers will discuss how platforms are or could be used for rapid response and deployment to combat pandemics such as COVID-19 and Influenza. The panel will engage in an integrated discussion on vaccine and therapeutic immunization strategies and how these technology platforms will address the increasing challenges in new vaccine development.
